Immunome Inc (NASDAQ: IMNM) is 62.43% higher on its value in year-to-date trading and has touched a low of $4.44 and a high of $30.96 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The IMNM stock was last observed hovering at around $18.40 in the last trading session, with the day’s loss setting it -1.02%.
Currently trading at $17.38, the stock is -21.30% and -24.75% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.95 million and changing -5.54% at the moment leaves the stock 40.29% off its SMA200. IMNM registered 216.00% gain for a year compared to 6-month gain of 94.84%.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -21.36% loss in the last 1 month and extending the period to 3 months gives it a 24.14%, and is -14.51% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 7.03% over the week and 7.12% over the month.
Immunome Inc (IMNM) has around 55 employees, a market worth around $1.04B and $14.02M in sales. Profit margin for the company is -761.92%. Distance from 52-week low is 291.44% and -43.86% from its 52-week high. The company has generated returns on investments over the last 12 months (-88.11%).
The EPS is expected to grow by 64.17% this year
The shares outstanding are 59.69M, and float is at 48.31M with Short Float at 6.71%.
Immunome Inc (IMNM) Insider Activity
The most recent transaction is an insider purchase by SIEGALL CLAY B, the company’s President and CEO. SEC filings show that SIEGALL CLAY B bought 169,204 shares of the company’s common stock on Oct 02 ’23 at a price of $5.91 per share for a total of $1.0 million. Following the purchase, the insider now owns 0.32 million shares.
Immunome Inc disclosed in a document filed with the SEC on Oct 02 ’23 that Turner Bruce (Chief Strategy Officer) bought a total of 42,300 shares of the company’s common stock. The trade occurred on Oct 02 ’23 and was made at $5.91 per share for $0.25 million. Following the transaction, the insider now directly holds 42300.0 shares of the IMNM stock.
